Cancer immunotherapy in patients with brain metastases
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Cancer immunotherapy in patients with brain metastases. / Caponnetto, Salvatore; Draghi, Arianna; Borch, Troels Holz; Nuti, Marianna; Cortesi, Enrico; Svane, Inge Marie; Donia, Marco.
I: Cancer Immunology, Immunotherapy, Bind 67, Nr. 5, 2018, s. 703-711.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cancer immunotherapy in patients with brain metastases
AU - Caponnetto, Salvatore
AU - Draghi, Arianna
AU - Borch, Troels Holz
AU - Nuti, Marianna
AU - Cortesi, Enrico
AU - Svane, Inge Marie
AU - Donia, Marco
PY - 2018
Y1 - 2018
N2 - The exclusion of “real-world” patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a “real-world” setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.
AB - The exclusion of “real-world” patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a “real-world” setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.
KW - Brain metastases
KW - Cancer immunotherapy
KW - Check-point inhibitors
KW - Ipilimumab
KW - Nivolumab
KW - Pembrolizumab
U2 - 10.1007/s00262-018-2146-8
DO - 10.1007/s00262-018-2146-8
M3 - Review
C2 - 29520474
AN - SCOPUS:85043374117
VL - 67
SP - 703
EP - 711
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
SN - 0340-7004
IS - 5
ER -
ID: 215186255